This is an experimental study to evaluate the safety and effectiveness of PSMA-targeted CAR-T cells in the treatment of castration-resistant prostate cancer.
Male patients aged from 18 to 75 years old;
The patients' ECOG score ≤ 2;
Previous new endocrine therapy is ineffective;
Past treatment with too much citabine or cabatase is ineffective.
Infectious diseases (such as HIV, active hepatitis B or C infection, active tuberculosis, etc.);
Feasibility evaluation screening proves that the transfection of targeted lymphocytes is less than 10% or the amplification under the co-stimulation of CD3/CD28 is insufficient (< 5 times);
The vital signs are abnormal and those who cannot cooperate with the inspectors;
Those with mental illness or mental illness who can't cooperate with treatment and curative effect evaluation;
Single group
CAR-T cell immunotherapy
Biological/VaccineThis CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at PSMA.
Safety Evaluation:Incidence and Severity of Adverse Events
To evaluate the incidence and severity of possible adverse events within one month after targeted PSMA CAR-T infusion, including cytokine release syndrome and on-target toxicity.
Effectiveness Evaluation
In order to observe the efficacy of CAR-T cells after infusion, total remission rate (ORR), complete remission (CR), partial remission (PR), disease stability (SD) or progression (PD) will be used for evaluation.
Progression-free Survival (PFS)
Progression-free survival (PFS) time
Overall Survival (OS)
Overall survival (OS) time
Click on the lead sponsor to view all of their trials.
The Affiliated Hospital of Xuzhou Medical University
Lead sponsor
Xuzhou Medical University
Collaborator
